A Randomised Double-blind (Sponsor Open), Placebo Controlled, Single Ascending Dose, First Time in Human Study in Participants With Mild to Moderate Asthma to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3511294 Administered Subcutaneously
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
At a glance
- Drugs GSK-3511294 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 12 Oct 2018 Planned number of patients changed from 72 to 48.
- 31 Aug 2018 Biomarkers information updated
- 15 Feb 2018 Planned primary completion date changed from 6 Dec 2018 to 24 Sep 2019.